Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 15/20 | 0.77 |
| ▸ | CLK1 | P49759 | 2/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.53 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.53 |
| ▸ | PARP1 | P09874 | 2/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL141989 | 0.92 | JAK2 (0.68) | JAK2PARP1CASP1 | |
| SCHEMBL140179 | 0.90 | JAK2 (0.66) | JAK2DYRK1APARP1 | |
| SCHEMBL142655 | 0.90 | JAK2 (0.78) | JAK2DYRK1APLA2G2A | |
| SCHEMBL141522 | 0.89 | JAK2 (0.80) | JAK2DYRK1APLA2G2AALOX15 | |
| SCHEMBL140203 | 0.87 | JAK2 (0.60) | JAK2PARP1 | |
| SCHEMBL142210 | 0.87 | JAK2 (0.63) | JAK2PARP1 | |
| SCHEMBL143862 | 0.87 | JAK2 (1.00) | JAK2DYRK1APLA2G2A | |
| SCHEMBL139852 | 0.85 | JAK2 (0.62) | JAK2CLK1CDK5DYRK1ACDK5R1 | |
| SCHEMBL142279 | 0.84 | JAK2 (1.00) | JAK2PARP1CASP1PLA2G2AALOX15 | |
| SCHEMBL141226 | 0.81 | JAK2 (0.56) | JAK2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815840-B2 | Carbazole and carboline kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815840-B2 | Carbazole and carboline kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| EP-2370407-B1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-18 | — | — | EP | disclosed |
| EP-2370407-B1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-18 | — | — | EP | disclosed |
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| EP-2370407-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010080474-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010080474-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | JAK2, JAK1, JAK3 | JAK2 1/4885CLK1 464/4885CDK5 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.